These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 24832022)

  • 81. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.
    Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS
    J Antimicrob Chemother; 2008 Jun; 61(6):1369-75. PubMed ID: 18367459
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
    Cai X; Yang Z; Dai J; Chen K; Zhang L; Ni W; Wei C; Cui J
    Int J Antimicrob Agents; 2017 May; 49(5):609-616. PubMed ID: 28315729
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Is tigecyclin a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia?
    Tasbakan MS; Pullukcu H; Sipahi OR; Tasbakan MI; Aydemir S; Bacakoglu F
    J Chemother; 2011 Dec; 23(6):345-9. PubMed ID: 22233818
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
    Lenhard JR; Thamlikitkul V; Silveira FP; Garonzik SM; Tao X; Forrest A; Soo Shin B; Kaye KS; Bulitta JB; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2017 May; 72(5):1415-1420. PubMed ID: 28333347
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A nightmare for haematology clinics: extensively drug-resistant (XDR) Acinetobacter baumannnii.
    Metan G; Pala Ç; Kaynar L; Cevahir F; Alp E
    Infez Med; 2014 Dec; 22(4):277-82. PubMed ID: 25551842
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii.
    Amat T; Gutiérrez-Pizarraya A; Machuca I; Gracia-Ahufinger I; Pérez-Nadales E; Torre-Giménez Á; Garnacho-Montero J; Cisneros JM; Torre-Cisneros J
    Clin Microbiol Infect; 2018 Jun; 24(6):630-634. PubMed ID: 28970161
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients.
    Tsioutis C; Kritsotakis EI; Karageorgos SA; Stratakou S; Psarologakis C; Kokkini S; Gikas A
    Int J Antimicrob Agents; 2016 Nov; 48(5):492-497. PubMed ID: 27542315
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.
    Pongpech P; Amornnopparattanakul S; Panapakdee S; Fungwithaya S; Nannha P; Dhiraputra C; Leelarasamee A
    J Med Assoc Thai; 2010 Feb; 93(2):161-71. PubMed ID: 20301995
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence.
    Falagas ME; Vardakas KZ; Roussos NS
    Int J Antimicrob Agents; 2015 Sep; 46(3):231-41. PubMed ID: 26070662
    [TBL] [Abstract][Full Text] [Related]  

  • 90. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii.
    Mutlu Yilmaz E; Sunbul M; Aksoy A; Yilmaz H; Guney AK; Guvenc T
    Int J Antimicrob Agents; 2012 Oct; 40(4):332-6. PubMed ID: 22831842
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model.
    Fan B; Guan J; Wang X; Cong Y
    PLoS One; 2016; 11(6):e0157757. PubMed ID: 27315107
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Antimicrobial resistance and existence of metallo-beta-lactamase in Acinetobacter species isolated from adult patients].
    Eser OK; Ergin A; Hasçelik G
    Mikrobiyol Bul; 2009 Jul; 43(3):383-90. PubMed ID: 19795613
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates.
    Kiratisin P; Apisarnthanarak A; Kaewdaeng S
    Int J Antimicrob Agents; 2010 Sep; 36(3):243-6. PubMed ID: 20541913
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii.
    Montero A; Ariza J; Corbella X; Doménech A; Cabellos C; Ayats J; Tubau F; Ardanuy C; Gudiol F
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1946-52. PubMed ID: 12019113
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence.
    Falagas ME; Lourida P; Poulikakos P; Rafailidis PI; Tansarli GS
    Antimicrob Agents Chemother; 2014; 58(2):654-63. PubMed ID: 24080646
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.
    Jain R; Danziger LH
    Ann Pharmacother; 2004 Sep; 38(9):1449-59. PubMed ID: 15280512
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality.
    Hernández-Torres A; García-Vázquez E; Gómez J; Canteras M; Ruiz J; Yagüe G
    Med Clin (Barc); 2012 May; 138(15):650-5. PubMed ID: 22093403
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Investigation of Extensively Drug-Resistant blaOXA-23-Producing Acinetobacter baumannii Spread in a Greek Hospital.
    Mavroidi A; Katsiari M; Palla E; Likousi S; Roussou Z; Nikolaou C; Platsouka ED
    Microb Drug Resist; 2017 Jun; 23(4):488-493. PubMed ID: 27728770
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter?
    Cooper TW; Pass SE; Brouse SD; Hall RG
    Ann Pharmacother; 2011 Feb; 45(2):229-40. PubMed ID: 21304038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.